REZUROCK is definitely an inhibitor of UGT1A1. Coadministration of REZUROCK using a UGT1A1 substrate lowered plasma concentrations from the glucuronide metabolite, which can increase the threat of adverse reactions relevant to delicate substrates of UGT1A1Our professional medical and scientific workforce continues investigation to enhance therapies